Dr. Sujuan Ba serves as the President and COO of the National Foundation for Cancer Research. She is also the founder and CEO of the Asian Fund for Cancer Research. Dr. Ba has served continuously for 13 years as co-Chair of the Prize Selection Committee of the Szent-Györgyi Prize for Progress in Cancer Research. The Committee is comprised of academic leaders and pharmaceutical industry executives, and the annual Prize has become one of the premier cancer research awards in the world.
Dr. Ba co-founded and serves as a founding board member of the Global Coalition for Adaptive Research (GCAR), the organizing body leading the global implementation of GBM AGILE, a groundbreaking adaptive clinical trial initiative designed to produce new and better treatments for glioblastoma multiforme, a fatal brain cancer. She is also a co-founder of the International Cancer Impact Fund, the former President of the Chinese Biopharmaceutical Association, and serves on the International Consulting Committee of the China National Research Center for Translational Medicine (Shanghai). She also sits on the Scientific Advisory Boards of Medelis, Inc. (Fountain Hills, Arizona) and Immunicom Inc. (San Diego).
Dr. Ba is a member of the Editorial Board of the Chinese Journal of Cancer and formerly served on the Membership Committee of the International Union against Cancer (Geneva) and the Activity Steering Committee of the Cosmos Club (Washington, DC). She also belongs to BayHelix, an invitation-only organization of leaders of Chinese origin involved globally in life sciences and health.
She was recognized in 2017 by the Chinese Medical Doctor Association for her outstanding contributions to international cooperation and was named one of the “Top 300 Women Leaders in Global Health” in 2015 by the Graduate Institute of International and Development Studies’ Global Health Programme.
Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.
Learn more about Dr. Sujuan Ba here.